Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Weitere Synonyme anzeigen
Wählen Sie die gewünschte Spezies
the miR494/CDK6 axis has a significant tumorsuppressive effect on osteosarcoma.
High CDK6 expression is associated with bladder carcinoma.
Results suggest that dysregulation and activation of the cell cycle proteins CDK4 (zeige CDK4 Proteine)/CDK6-CCND1 (zeige CCND1 Proteine)-phospho-RB1 (zeige RB1 Proteine) axis is associated with higher proliferative index in neuroendocrine tumors (NETs).
Ongoing trials of doublet and triplet targeted therapies containing ribociclib seek to identify optimal CDK4/6 (zeige CDK4 Proteine)-based targeted combination regimens for various tumor types and advance the field of precision therapeutics in oncology
Transfection of cells with ClC-3 (zeige CLCN3 Proteine) siRNA decreased the expression of cyclin D1 (zeige CCND1 Proteine), cyclin dependent kinase 4 (zeige CDK4 Proteine) and 6, and increased the expression of cyclin dependent kinase (zeige CDK1 Proteine) inhibitors (CDKIs), p21 (zeige CDKN1A Proteine) and p27 (zeige PAK2 Proteine). Pretreatments of cells with p21 (zeige CDKN1A Proteine) and p27 (zeige PAK2 Proteine) siRNAs depleted the inhibitory effects of ClC-3 (zeige CLCN3 Proteine) siRNA on the expression of CDK4 (zeige CDK4 Proteine) and CDK6, but not on that of cyclin D1 (zeige CCND1 Proteine)
miRNA-195 was associated with tumor malignancy grade and might be involved in the development and progression of OVC. In addition, CDK6 was predicted to be a target gene of miRNA-195 and obviously increased in both OVC and OSCC.
Palbociclib induces activation of AMPK (zeige PRKAA1 Proteine) and inhibits hepatocellular carcinoma in a CDK4/6 (zeige CDK4 Proteine)-independent manner
The combination of ribociclib, a dual inhibitor of cyclin-dependent kinase (CDK) 4 and 6, and the ALK inhibitor ceritinib demonstrated higher cytotoxicity and synergy scores (P = 0.006) in cell lines with ALK mutations as compared with cell lines lacking mutations or alterations in ALK .
CDK4/6 (zeige CDK4 Proteine) inhibition suppressed cell cycle progression of ER+/HER2 (zeige ERBB2 Proteine)- brreast cancer models.
Proliferating tumor stem cells with high telomerase expression are suitable targets for CDK4/6 (zeige CDK4 Proteine) inhibitor, palbociclib.
These results indicate that p18 (zeige CDKN2C Proteine) blocks reprogramming by targeting Cdk4/6 (zeige CDK4 Proteine)-mediated cell cycle regulation.
CDK6 kinase activity negatively regulates the conversion of fat-storing cells into fat-burning cells by suppressing RUNX1 (zeige RUNX1 Proteine), and may be a therapeutic target for the treatment of obesity and related metabolic diseases
Cdk6 interacts with a number of proteins involved in cytoskeleton organization. Cdk6 regulates the transcription of a panel of genes involved in actin (de-)polymerization.
PD 0332991 (PD), an FDA-approved selective inhibitor of cyclin-dependent kinase 4/6 (CDK4/6 (zeige CDK4 Proteine)), prevents radiation-induced lethal intestinal injury in mice. Treating mice with PD or a structurally distinct CDK4/6 (zeige CDK4 Proteine) inhibitor prior to radiation blocked proliferation and crypt apoptosis and improved crypt regeneration.
CDK6-mediated suppression of CD25 (zeige IL2RA Proteine) is required for initiation of T-ALL by activated Notch1 (zeige NOTCH1 Proteine). . Pharmacologic inhibition of CDK6 kinase induces CD25 (zeige IL2RA Proteine) and RUNX1 (zeige RUNX1 Proteine) expression, cell cycle arrest and apoptosis in mouse and human T-ALL.
Fbxo7 (zeige FBXO7 Proteine)-deficient immature thymocytes failed to undergo expansion in the thymus due to a lack of Cdk6 activity, while mature T cells showed enhanced proliferative capacity upon T-cell receptor engagement due to reduced p27 (zeige CDKN1B Proteine) levels. These studies reveal differential cell cycle regulation by Fbxo7 (zeige FBXO7 Proteine) at different stages in T-cell development.
Taken together, our results suggested that microRNA-33 enhanced the replicative senescence of MEFs potentially by suppressing CDK6 expression.
Data show that E11/glycoprotein 38 (zeige PDPN Proteine)(GP38 (zeige PDPN Proteine)) was up-regulated upon SEMA3A (zeige SEMA3A Proteine) stimulation, and cyclin-dependent kinase 6 (CDK6) was down-regulated in a time-dependent manner.
Notch3 (zeige NOTCH3 Proteine) transcription and growth of lymphoma cells was dependent on CDK6.
CDK6 is an important regulator of stem cell activation and an essential component of a transcriptional complex that suppresses Egr1 (zeige EGR1 Proteine) in hematopoietic and leukemic stem cell activation
the T-1075C SNP of bovine CDK6 is significantly associated with body length and heart girth
The protein encoded by this gene is a member of the cyclin-dependent protein kinase (CDK) family. CDK family members are highly similar to the gene products of Saccharomyces cerevisiae cdc28, and Schizosaccharomyces pombe cdc2, and are known to be important regulators of cell cycle progression. This kinase is a catalytic subunit of the protein kinase complex that is important for cell cycle G1 phase progression and G1/S transition. The activity of this kinase first appears in mid-G1 phase, which is controlled by the regulatory subunits including D-type cyclins and members of INK4 family of CDK inhibitors. This kinase, as well as CDK4, has been shown to phosphorylate, and thus regulate the activity of, tumor suppressor protein Rb. Expression of this gene is up-regulated in some types of cancer. Multiple alternatively spliced variants, encoding the same protein, have been identified.
cyclin-dependent kinase 6
, cell division protein kinase 6-like
, cell division protein kinase 6
, serine/threonine-protein kinase PLSTIRE
, CR2 protein kinase